PMV Pharma reports Q3 2026 results, plans rezatapopt NDA filing in Q1 2027Nov 10Quarterly updatePMV Pharmaceuticals, Increzatapopt
PMV Pharma names Matt Eckler to board ahead of planned NDA filingOct 5PeoplePMV Pharmaceuticals, Increzatapopt
PMV Pharma finalizes $50.8 million offering, details rezatapopt data and NDA timelineSep 1FinancingPMV Pharmaceuticals, Increzatapopt
PMV Pharma reports 46% ORR in ovarian cancer cohort of rezatapopt trialAug 31Clinical readoutPMV Pharmaceuticals, Increzatapopt
PMV Pharma completes PYNNACLE enrollment, targets Q1 2027 NDA for rezatapoptAug 14Quarterly updatePMV Pharmaceuticals, Increzatapopt